BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15837986)

  • 21. Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients.
    Tezuka K; Onoda N; Takashima T; Takagaki K; Ishikawa T; Wakasa T; Wakasa K; Hirakawa K
    Oncol Rep; 2007 May; 17(5):997-1003. PubMed ID: 17390035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool.
    Sanghani M; Balk E; Cady B; Wazer D
    Am J Clin Oncol; 2007 Oct; 30(5):473-80. PubMed ID: 17921706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
    Jung SY; Han W; Lee JW; Ko E; Kim E; Yu JH; Moon HG; Park IA; Oh DY; Im SA; Kim TY; Hwang KT; Kim SW; Noh DY
    Ann Surg Oncol; 2009 May; 16(5):1112-21. PubMed ID: 19219507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and feasibility of breast conserving therapy in Indian women: two decades of experience at Tata Memorial Hospital.
    Dinshaw KA; Sarin R; Budrukkar AN; Shrivastava SK; Deshpande DD; Chinoy RF; Badwe R; Hawaldar R
    J Surg Oncol; 2006 Aug; 94(2):105-13. PubMed ID: 16847919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
    Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy.
    Truong PT; Lesperance M; Culhaci A; Kader HA; Speers CH; Olivotto IA
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):175-82. PubMed ID: 15850919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
    Truong PT; Jones SO; Kader HA; Wai ES; Speers CH; Alexander AS; Olivotto IA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):357-64. PubMed ID: 18676091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis.
    Reimer T; Fietkau R; Markmann S; Stachs A; Gerber B
    Ann Surg Oncol; 2008 Feb; 15(2):472-7. PubMed ID: 17987339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
    Jeruss JS; Mittendorf EA; Tucker SL; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
    J Clin Oncol; 2008 Jan; 26(2):246-52. PubMed ID: 18056680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy.
    Quek ML; Stein JP; Nichols PW; Cai J; Miranda G; Groshen S; Daneshmand S; Skinner EC; Skinner DG
    J Urol; 2005 Jul; 174(1):103-6. PubMed ID: 15947587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
    Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
    Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
    Wapnir IL; Anderson SJ; Mamounas EP; Geyer CE; Jeong JH; Tan-Chiu E; Fisher B; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2028-37. PubMed ID: 16648502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
    J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.